Testing Principles
The plasma Hcy concentrations are measured by enzyme conversion method. Hcy is first reduced by the oxidant and is decomposed by the gene recombinase afterwards. The product react with the chromogenic agent, emitting fluorescent light of 710 nm while being simulated by the light of 660 nm. The plasma Hcy concentrations can be calculated from the fluorescence differentials.

Product Features

European technology & imported raw materials of gene synthetic enzyme; 

Pre-filled single tube is fast and convenient for individual tests; 

Lyophilized preparation features high stability, and is effective for 16 months;

Fluorescence colorimetric method guarantees high sensitivity and specificity; 

Deliver quantitative results within 10 minutes, making the kit suitable for point-of-care testing ( POCT ); 

Standard reagent included; 

Both batch and random testing are available;

The 4-point calibration curve guarantees the accuracy of the test results; 

Wide linear range of 1-100 mol/L & linear correlation coefficient (r)≥0.990; 

Accuracy: absolute deviation is within ±10 % 

Precision : intra CV% ≤ 5%; inter CV% ≤ 5%; 

It meets the target requirements of commercial quality control products.

System Composition

1. Micro Fluorescence Detector

2. Homocysteine Rapid Test Kit   

3. Optional Accessories
For detailed system composition information, please download here

Target Departments
The homocysteine (Hcy) rapid test system is applicable in laboratories of medicine, neurology, endocrinology, urology, maternal and children health care and physical examination center.

Clinical Significance
Homocysteine (Hcy) is an independent risk factor for cardiovascular diseases and the risk increases along with the increase of Hcy concentration. It is revealed that for every 5  μmol/L increase of Hcy concentration, there would be a risk increase of 60% for male coronary heart disease(CHD) patients and 8% for female patients.

According to the recent studies, the Hcy concentration of typeⅡdiabetics is higher than the normal level and is significantly associated with the levels with FBG, HbAlc and the duration of diabetes. It is indicated that for every increase of 5  μmol/L , the death rate of diabetics would increase by 3 times in the next 5 years. The Hcy levels of Chronic kidney disease (CKD) patients are normally higher owing to the excretory dysfunction of Hcy, leading to a higher risk of developing atherosclerosis and cardiovascular diseases.

Recent reseaches have shown that hyperhomocysteinemia (HHcy) is an independent risk factor for fetal vascular diseases and birth defects and the metabolic disorder of Hcy plays an important role in the pathogenesis of congenital heart defects. It is demonstrated that there is a significant relationship between the maternal plasma Hcy level and fetal birth defects. Maternal hyperhomocysteinemia in the gestational period is one of the risk factors for fetus birth defects, especially in congenital heart malformations and neural tube defects. It suggests that the plasma Hcy can be taken as an indicator of prenatal screening for birth defects, and birth defects are likely to occur if the maternal suffers from hyperhomocysteinemia. There is a positive correlation between maternal plasma Hcy and fetal plasma Hcy, and  therefore the determination of maternal Hcy values can predict the level of Hcy in fetus.

In general, Hcy levels in blood can be an efficient and precise indicator in the diagnosis of diabetic nephropathy, cardiovascular diseases and the screening of fetus birth defects.